Showing results (21-30 of 83) with videos related to
Sort By:
Pageof 9
Journal of the American Academy of Dermatology|December 23, 2006
Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphomaJacob A Sepmeyer, John P Greer, Tatsuki Koyama, et al.Ocular Oncology and Pathology|August 2, 2019
Blastic Transformation of a Mantle Cell Lymphoma Presenting as an Enlarging Unilateral Orbital MassMatthew A De Niear, John P Greer, Adam Seegmiller, et al.British Journal of Haematology|November 13, 2007
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivoNishitha Reddy, Francisco J Hernandez-Ilizaliturri, George Deeb, et al.Clinical Lymphoma & Myeloma|March 2, 2006
Non-Hodgkin's lymphoma involving the liver: clinical and therapeutic considerationsJ Stuart Salmon, Mary Ann Thompson, Ronald C Arildsen, et al.Journal of the American Academy of Dermatology|April 25, 2006
Conjugal transformed mycosis fungoides: the unknown role of viral infection and environmental exposures in the development of cutaneous T-cell lymphomaAdriana N Schmidt, Jason B Robbins, John P Greer, et al.Seminars in Oncology|May 15, 2016
Cutaneous manifestations and management of hematologic neoplasmsOlalekan O Oluwole, John A Zic, Jonathan J Douds, et al.Experimental Hematology|October 8, 2013
Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphomaNishitha M Reddy, Olalekan Oluwole, John P Greer, et al.Journal of the American Academy of Dermatology|August 2, 2003
Large B-cell lymphoma of the leg: clinical and pathologic characteristics in a North American seriesBeth L Brogan, John A Zic, Marsha C Kinney, et al.The Lancet. Oncology|July 14, 2022
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trialJohn M Pagel, Jacob D Soumerai, Nishitha Reddy, et al.Molecular Imaging and Biology|October 11, 2003
2-deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphomaDominique Delbeke, William H Martin, David S Morgan, et al.Pageof 9